文献速递美容整形创面修复

自体脂肪移植辅助疗法的循证评估:潜在药物排名

An Evidence-Based Assessment of Adjuvant Therapy in Autologous Fat Transfer: Ranking of the Potential Agents.
PubMed 文献 · Ann Plast Surg · 2026-01-30

本研究通过靶向文献综述和加权评分分析,从FDA批准、动物模型有效性、剂量优化、人体安全性、机制合理性及成本效益6个维度评估7种自体脂肪移植辅助药物。去铁胺以22/28分排名第一,临床前证据显示其通过促血管生成、减少氧化应激提高脂肪移植物保留率最高达50%。

要点

  • 去铁胺评分最高(22/28),临床前证据支持其促血管生成和减少氧化应激。
  • 胰岛素联合β-FGF评分18,有效性有前景但缺乏FDA批准。
  • 肉毒毒素A评分15,因脂肪移植中疗效数据不一致而受限。

核心结论

  • 去铁胺因兼具铁螯合剂和缺氧模拟剂双重作用,减少氧化损伤并促进血管再生,成为最具转化潜力的候选药物。

研究设计与样本

  • 靶向文献综述,采用加权评分分析评估7种辅助药物,评分框架包含6个关键领域。

主要发现

  • 去铁胺总分最高(22/28),临床前证据支持其提高脂肪移植物保留率最高达50%。
  • 胰岛素联合β-FGF得分18,有效性有前景但缺乏FDA批准。
  • 透明质酸水凝胶和泊洛沙姆分别得分17和16。
  • 肉毒毒素A和前列腺素E2联合聚脱氧核糖核苷酸均得分15。
  • ADE4+内皮细胞得分14,因批准有限且改善脂肪移植物活力的结果不够有力。

关键数值与推荐

  • 评分框架6个领域:FDA人体使用批准、动物模型有效性、剂量优化、人体安全性、机制合理性、成本效益。
  • 前5个领域按证据强度1-5分评分,成本效益按1-3分评分,总分相加进行排名。

临床怎么用

  • 去铁胺可作为未来临床试验的首选候选辅助药物,但需进一步开展人体离体研究确定最佳递送方式和试验设计。

局限性

  • 本研究为靶向文献综述,证据主要来自临床前研究,缺乏人体临床试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Autologous fat transfer is widely used in reconstructive and aesthetic surgery; however, its efficacy is often limited by suboptimal fat graft survival. Various pharmacological adjuncts have been proposed to enhance fat graft viability. This study aims to assess and rank potential adjuvant agents based on their effectiveness, safety, Food and Drug Administration (FDA) approval for human use, and clinical applicability to identify the most promising candidate for future clinical trials. METHODS: In this targeted literature review, a weighted scoring analysis was conducted to evaluate several adjuncts proposed to improve fat graft viability. The scoring framework incorporated 6 key domains: FDA approval for human use, effectiveness in animal models, dosing optimization, safety in humans, mechanistic rationale, and cost-effectiveness. Each of the first 5 domains was scored on a 1-to-5 scale based on strength of supporting evidence, whereas cost-effectiveness was scored on a 1-to-3 scale. Total scores were calculated by summing all 6 domain scores, allowing a comparative ranking of adjuncts with the highest translational potential. The agents evaluated included deferoxamine, insulin with β-fibroblast growth factor, poloxamers, ADE4+ endothelial cells, hyaluronan hydrogel, botulinum toxin A, and a combination of prostaglandin E2 with polydeoxyribonucleotide. RESULTS: Deferoxamine received the highest total score (22/28) and demonstrated robust preclinical evidence supporting its ability to promote angiogenesis, reduce oxidative stress, and enhance fat graft retention by up to 50%. Insulin combined with β-fibroblast growth factor scored 18, showing promising effectiveness but limited by lack of FDA approval. Hyaluronan hydrogel and poloxamers followed with scores of 17 and 16, respectively. Botulinum toxin A scored 15, limited by inconsistencies in efficacy data in fat grafting. Prostaglandin E2 with polydeoxyribonucleotide scored 15, and ADE4+ endothelial cells scored 14 because of limited approval and less compelling results in improving fat graft viability. CONCLUSION: Deferoxamine emerged as the top translational candidate due to its dual role as an iron chelator and hypoxia-mimetic, reducing oxidative injury and promoting vascular regeneration. Our team is currently conducting ex vivo studies exposing human adipose grafts to deferoxamine and assessing viability with confocal microscopy. These results will inform optimal delivery and design of future clinical trials.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Sarpong C, Oh I, Bouz A, et al. An Evidence-Based Assessment of Adjuvant Therapy in Autologous Fat Transfer: Ranking of the Potential Agents. Ann Plast Surg. 2026. PMID: 41616257. doi:10.1097/SAP.0000000000004664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。